Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
15 Stocks Moving in Friday's Pre-Market Session
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) rose 42% to $3.21 in pre-market trading. AbCellera Biologics Inc. (NASDAQ: ABCL) rose 18% to $23.35 in pre-market trading.... 
Via Benzinga
Zymeworks' Zanidatamab Aces Mid-Stage Esophageal Cancer Trial
At the European Society of Medical Oncology Congress 2021 (ESMO21), Zymeworks Inc (NYSE: ZYME) presented encouraging early data on its HER2‑targeted bispecific antibody. Twenty-... 
Via Benzinga
Notable Beigene Insider Makes $4.62 Million Sale
Jane Huang, Cmo And Hematology at Beigene (NASDAQ:BGNE), made a large insider sell on September 13, according to a new SEC filing. What Happened: A Form 4 filing from the U.S.... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Leap Therapeutics Stock Is Moving Higher On Updated DKN-01 Combo Trial Data In Gastric Cancer
Leap Therapeutics Inc (NASDAQ: LPTX) announced updated data from the first-line cohort of the DisTinGuish Phase 2a trial evaluating DKN-01 combined with ... 
Via Benzinga
BeiGene's Brukinsa Scores FDA Approval For Marginal Zone Lymphoma
The FDA has granted accelerated approval to BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for relapsed or refractory (R/R) marginal zone lymphoma (... 
Via Benzinga
Exposures Product Safety
Unusual Options Activity Insight: BeiGene
BeiGene (NASDAQ:BGNE) shares experienced unusual options ... 
Via Benzinga
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
From BeiGene, Ltd.
Via Business Wire
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
Exposures COVID-19
3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go... 
Via Benzinga
Why Are Leap Therapeutics Shares Trading Higher On Monday?
Leap Therapeutics Inc (NASDAQ: LPTX) stock increased over 30% premarket as the investors are responding positively ahead of the Company’s presentation of new data... 
Via Benzinga
BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021
From BeiGene, Ltd.
Via Business Wire
Why BeiGene Stock Is Soaring This Week
The company won another FDA approval for blood cancer drug Brukinsa. 
Via The Motley Fool
Exposures Product Safety
BeiGene's Brukinsa Scores FDA Approval For Rare Blood Cancer Indication
The FDA has approved BeiGene Ltd (NASDAQ: BGNE) Brukinsa (zanubrutinib) for the treatment of adult patients with Waldenström's macroglobulinemia (WM).... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV... 
Via Benzinga
Exposures COVID-19 Product Safety
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström’s Macroglobulinemia
From BeiGene, Ltd.
Via Business Wire
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street; Crude Oil Rises Over 3%
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones surged more than 200 points in the previous session. Investors are awaiting earnings... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyngeal Cancer
From BeiGene, Ltd.
Via Business Wire
58 Biggest Movers From Friday
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares climbed 204.1% to close at $19.16 on Friday. Regencell Bioscience reported partial exercise of underwriter... 
Via Benzinga
BeiGene's Pediatric Tumor Drug Scores Conditional Approval In China
The China National Medical Products Administration (NMPA) granted conditional approval for BeiGene Ltd (NASDAQ: BGNE) - EUSA Pharma's (UK) ... 
Via Benzinga
BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients with High-Risk Neuroblastoma
From BeiGene, Ltd.
Via Business Wire
BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research on August 25, 2021
From BeiGene, Ltd.
Via Business Wire
BeiGene Reports Second Quarter 2021 Financial Results
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces Plans to Build New Manufacturing and Clinical R&D Center at Princeton West Innovation Park in Hopewell, New Jersey
From BeiGene, Ltd.
Via Business Wire
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
BeiGene's Brukinsa Prolongs Progression-Free Survival Compared To Chemo In Untreated Blood Cancer Patients
BeiGene Ltd (NASDAQ: BGNE) announced positive topline results from an interim analysis of the Phase 3 SEQUOIA trial comparing Brukinsa (zanubrutinib) to... 
Via Benzinga
BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
62 Biggest Movers From Yesterday
Gainers Flora Growth Corp. (NASDAQ: FLGC) surged 63.1% to close at $8.27. The Miami-based cannabis producer confirmed Tuesday it has signed a non-binding letter of intent to... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.